Raabya Rossenkhan
Overview
Explore the profile of Raabya Rossenkhan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2024 Mar;
15(1):2575.
PMID: 38519455
No abstract available.
2.
Juraska M, Bai H, deCamp A, Magaret C, Li L, Gillespie K, et al.
Proc Natl Acad Sci U S A
. 2024 Jan;
121(4):e2308942121.
PMID: 38241441
In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition...
3.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2023 Dec;
14(1):8299.
PMID: 38097552
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical...
4.
Seaton K, Huang Y, Karuna S, Heptinstall J, Brackett C, Chiong K, et al.
EBioMedicine
. 2023 Jun;
93:104590.
PMID: 37300931
Background: The phase 2b proof-of-concept Antibody Mediated Prevention (AMP) trials showed that VRC01, an anti-HIV-1 broadly neutralising antibody (bnAb), prevented acquisition of HIV-1 sensitive to VRC01. To inform future study...
5.
B Gilbert P, Huang Y, deCamp A, Karuna S, Zhang Y, Magaret C, et al.
Nat Med
. 2022 Aug;
28(9):1924-1932.
PMID: 35995954
The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show...
6.
Ford E, Sholukh A, Boytz R, Carmack S, Klock A, Phasouk K, et al.
J Clin Invest
. 2021 Mar;
131(9).
PMID: 33784252
Tissue-based T cells are important effectors in the prevention and control of mucosal viral infections; less is known about tissue-based B cells. We demonstrate that B cells and antibody-secreting cells...
7.
Rolland M, Tovanabutra S, Dearlove B, Li Y, Owen C, Lewitus E, et al.
PLoS Pathog
. 2020 Feb;
16(2):e1008179.
PMID: 32027734
Most HIV-1 infected individuals do not know their infection dates. Precise infection timing is crucial information for studies that document transmission networks or drug levels at infection. To improve infection...
8.
Rossenkhan R, Rolland M, Labuschagne J, Ferreira R, Magaret C, Carpp L, et al.
Viruses
. 2019 Jul;
11(7).
PMID: 31277299
Knowledge of the time of HIV-1 infection and the multiplicity of viruses that establish HIV-1 infection is crucial for the in-depth analysis of clinical prevention efficacy trial outcomes. Better estimation...
9.
Rossenkhan R, MacLeod I, Brumme Z, Magaret C, Sebunya T, Musonda R, et al.
AIDS Res Hum Retroviruses
. 2016 Jun;
32(10-11):1031-1045.
PMID: 27349335
Viral variants that predominate during early infection may exhibit constrained diversity compared with those found during chronic infection and could contain amino acid signature patterns that may enhance transmission, establish...
10.
Novitsky V, Wang R, Rossenkhan R, Moyo S, Essex M
Infect Genet Evol
. 2013 Mar;
19:361-8.
PMID: 23523818
Background: HIV-1 nucleotide substitution rates are central for understanding the evolution of HIV-1. Their accurate estimation is critical for analysis of viral dynamics, identification of divergence time of HIV variants,...